Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

The therapy, which targets hepatitis B surface antigen (HBsAg), showed substantial antiviral activity in individuals with advanced HBV-related hepatocellular carcinoma (HBV-HCC). In the trial ...

The first-line screening test, which detects the HBV surface antigen, is affordable and accessible in many low-income countries. But the second test, which uses PCR to measure viral load ...

Large-scale data on the hepatitis D virus (HDV)/hepatitis B virus (HBV) co-infection rate is needed to estimate the current epidemiology of HDV in China. This study aimed to estimate the current ...

Creative Diagnostics has announced its Hepatitis B Virus Surface Antigen L-proteins for Hepatitis B research. NEW YORK, NY, UNITED STATES, March 24, 2025 ...

They are considered protected if they have a hepatitis B surface antigen antibody (anti-HBs) titer of ≥10 mIU/mL after completing a full vaccination series. This study compared the effectiveness ...

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...